Abstract
Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 197-204 |
| Number of pages | 8 |
| Journal | Cardiology in Review |
| Volume | 16 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2008 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Lipid-altering therapy and Atrial fibrillation. / Bachmann, Justin M.; Majmudar, Maulik; Tompkins, Christine; Blumenthal, Roger S; Marine, Joseph.
In: Cardiology in Review, Vol. 16, No. 4, 07.2008, p. 197-204.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lipid-altering therapy and Atrial fibrillation
AU - Bachmann, Justin M.
AU - Majmudar, Maulik
AU - Tompkins, Christine
AU - Blumenthal, Roger S
AU - Marine, Joseph
PY - 2008/7
Y1 - 2008/7
N2 - Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.
AB - Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.
UR - http://www.scopus.com/inward/record.url?scp=49149085882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49149085882&partnerID=8YFLogxK
U2 - 10.1097/CRD.0b013e318177271d
DO - 10.1097/CRD.0b013e318177271d
M3 - Article
VL - 16
SP - 197
EP - 204
JO - Cardiology in Review
JF - Cardiology in Review
SN - 1061-5377
IS - 4
ER -